SCHEMBL2378151

SCHEMBL2378151

C[C@@H]1C[C@@H](NC(=O)OC(C)(C)C)CN(Cc2ccccc2)C1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
JAK1 P23458 1/20 0.47
KDM1A O60341 1/20 0.46
MAOB P27338 1/20 0.46
EPHX2 P34913 1/20 0.46
KCNA3 P22001 1/20 0.45
DRD2 P14416 4/20 0.43
NPFFR1 Q9GZQ6 1/20 0.43
NPFFR2 Q9Y5X5 1/20 0.43
MEN1 O00255 1/20 0.42
MCHR1 Q99705 1/20 0.42
FUCA1 P04066 2/20 0.42
HRH4 Q9H3N8 1/20 0.42
HRH3 Q9Y5N1 1/20 0.42
EIF2AK4 Q9P2K8 1/20 0.41
DRD4 P21917 1/20 0.41
DRD3 P35462 1/20 0.41
NAMPT P43490 1/20 0.41
CCR5 P51681 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1552482 1.00 KMT2A (0.60) KMT2AL3MBTL1JAK1KDM1AMAOB
SCHEMBL19051699 1.00 KMT2A (0.60) KMT2AL3MBTL1JAK1KDM1AMAOB
SCHEMBL30404117 1.00 KMT2A (0.60) KMT2AL3MBTL1JAK1KDM1AMAOB
SCHEMBL1552484 1.00 KMT2A (0.60) KMT2AL3MBTL1JAK1KDM1AMAOB
SCHEMBL13520171 1.00 KMT2A (0.60) KMT2AL3MBTL1JAK1KDM1AMAOB
SCHEMBL9929564 1.00 KMT2A (0.60) KMT2AL3MBTL1JAK1KDM1AMAOB
SCHEMBL17304781 0.93 KMT2A (0.65) KMT2AL3MBTL1JAK1KDM1AMAOB
SCHEMBL1815532 0.90 KMT2A (0.65) KMT2AL3MBTL1JAK1KDM1AMAOB
SCHEMBL25263326 0.88 KMT2A (0.60) KMT2AL3MBTL1JAK1KDM1AMAOB
SCHEMBL21166304 0.88 KMT2A (0.60) KMT2AL3MBTL1JAK1KDM1AMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3668863-B1 TRICYCLIC COMPOUNDS AS HISTONE METHYL-TRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS INC (US) 2025-03-19 EP disclosed
US-11661410-B2 Tricyclic compounds as histone methyltransferase inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2023-05-30 US disclosed
US-20230002351-A1 TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. 2023-01-05 US disclosed
EP-3668863-A1 TRICYCLIC COMPOUNDS AS HISTONE METHYL-TRANSFERASE INHIBITORS Global Blood Therapeutics, Inc. (US) 2020-06-24 EP disclosed
WO-2019036377-A1 TRICYCLIC COMPOUNDS AS HISTONE METHYL-TRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. (US) 2019-02-21 WO disclosed
EP-2362775-B1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC (US) 2015-08-05 EP disclosed
US-8618103-B2 Inhibitors of JAK HOFFMANN-LA ROCHE INC. (US) 2013-12-31 US disclosed
EP-2475667-A1 INHIBITORS OF JAK F. Hoffmann-La Roche AG (CH) 2012-07-18 EP disclosed
US-20110275611-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC 2011-11-10 US disclosed
US-20110275611-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC 2011-11-10 US disclosed
EP-2373653-A1 PYRROLOPYRAZINYL UREA KINASE INHIBITORS F. Hoffmann-La Roche AG (CH) 2011-10-12 EP disclosed
US-8012974-B2 Pyrrolopyrazinyl urea kinase inhibitors ROCHE PALO ALTO LLC (US) 2011-09-06 US disclosed
WO-2011029804-A1 INHIBITORS OF JAK F. HOFFMANN-LA ROCHE AG (CH) 2011-03-17 WO disclosed
US-20110059118-A1 INHIBITORS OF JAK DE VICENTE FIDALGO JAVIER 2011-03-10 US disclosed
WO-2010063634-A1 PYRROLOPYRAZINYL UREA KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-06-10 WO disclosed
US-20100144745-A1 Pyrrolopyrazinyl Urea Kinase Inhibitors ROCHE PALO ALTO LLC 2010-06-10 US disclosed
WO-2010059658-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC (US) 2010-05-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002351-A1 TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS EHMT1, EHMT2, BMI1 KMT2A 5/4885L3MBTL1 52/4885JAK1 2739/4885
US-20110275611-A1 CHEMICAL COMPOUNDS PDK1, PDK2, PDK3 KMT2A 2173/4885L3MBTL1 3017/4885JAK1 1096/4885
US-11661410-B2 Tricyclic compounds as histone methyltransferase inhibitors EHMT1, EHMT2, BMI1 KMT2A 5/4885L3MBTL1 52/4885JAK1 2739/4885
US-20110059118-A1 INHIBITORS OF JAK JAK1, JAK3, JAK2 KMT2A 523/4885L3MBTL1 2592/4885JAK1 1/4885
US-20100144745-A1 Pyrrolopyrazinyl Urea Kinase Inhibitors JAK1, JAK3, ULK3 KMT2A 1814/4885L3MBTL1 3474/4885JAK1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.